4/25/23, 9:49 AMDEA Reports Widespread Threat of Fentanyl Mixed with Xylazine | DEA.gov

Page 1 of 3https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine

</>

Get Updates<https://service.govdelivery.com/accounts/usdojdea/subscriber/new>

Scam Alert

<https://www.dea.gov/scam -alert>

English </alert/dea-

reports-

widespread-

threat-

fentanyl-

mixed-

xylazine>

Search DEA.gov

Submit A Tip </submit-tip>

An o!icial website of the United States government Here’s how you know

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine WASHINGTON – The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as “Tranq,” is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use.  

“Xylazine is making the deadliest drug threat our country has ever faced, fentanyl, even deadlier,” said Administrator Milgram. “DEA has seized xylazine and fentanyl mixtures in 48 of 50 States. The DEA Laboratory System is reporting that in 2022 approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine.”

Xylazine and fentanyl drug mixtures place users at a higher risk of suffering a fatal drug poisoning. Because xylazine is not an opioid, naloxone (Narcan) does not reverse its effects. Still, experts always recommend administering naloxone if someone might be suffering a drug poisoning. People who inject drug mixtures containing xylazine also can develop severe wounds, including necrosis —the rotting of human tissue—that may lead to amputation.

According to the CDC, 107,735 Americans died between August 2021 and August 2022 from drug poisonings, with 66 percent of those deaths involving synthetic opioids like fentanyl. The Sinaloa Cartel and Jalisco Cartel in Mexico, using chemicals largely sourced from China, are primarily responsible for the vast majority of the fentanyl that is being trafficked in communities across the

PUBLICSAFETYALERT

4/25/23, 9:49 AMDEA Reports Widespread Threat of Fentanyl Mixed with Xylazine | DEA.gov

Page 2 of 3https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine

SAMHSA Behavioral Health Treatment Locator Address, city, state or zip code Go

Who We Are </who-we-

are>

About </who-we-are/about>

Domestic Divisions </divisions>

Foreign Offices </foreign-offices>

Contact Us </who-we-

are/contact-us>

DEA Museum <https://museum.dea.gov/>

What We Do </what-we-

do>

Drug Prevention </what-

we-do/education-and-

prevention>

Law Enforcement </law-enforcement>

Diversion Control Division <https://www.deadiversion.usdoj.gov>

News </news>

Careers </careers>

Overview </careers>

Special Agent </careers/special-agent>

Diversion Investigator </careers/diversion-

investigator>

Intelligence Research Specialist </careers/intelligence-

research-specialist>

Resources </resources>

Drug Information </drug-information>

Employee Assistance Program </resources/eap>

Equal Opportunity Employer </how-to-

apply/equal-opportunity-

employer>

FOIA </foia>

Publications

Media Galleries </resources/media-galleries>

VWAP </resources/vwap>

Doing Business with the DEA </resources/doing-business-

dea>

Overview </resources/doing-business-

dea>

Current Vendors </doing-business-dea/current-

vendors>

Prospective Vendors </doing-business-

dea/prospective-vendors>

Security Clauses </doing-business/security-

clauses>

Security Forms </doing-

business-dea/security-forms>

Small Business Program </doing-business-

dea/small-business>

Policies <>

Accessibility, Plug-ins & Policy </resources/accessibility%20and%20policy>

Legal Policies & Disclaimers <https://www.justice.gov/espanol/politicas-

legales-y-descargos-de-

responsabilidades>

No FEAR Act <https://www.justice.gov/jmd/no-

fear-act-notice-november-2-

2006>

Privacy Policy <http://www.justice.gov/spanish/privacy_spanish.html>

U.S. Department of Justice EEO Policy <https://www.justice.gov/jmd/file/790081/download>

USA.gov <https://www.usa.gov/espanol/>

Whistleblower Protection <https://oig.justice.gov/hotline/whistleblower-

protection>

United States.

FDA recently communicated to health care providers about the risks to patients exposed to xylazine in illicit drugs. A copy of that communication can be found here: FDA alerts healthcare professionals of risks to patients exposed to xylazine in illicit drugs. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs>

 

###

 

The DEA issues Public Safety Alerts to warn the public of new, emerging threats to the safety and health of the American people. The DEA last issued a Public Safety Alert in September 2021 warning the public about increases in the lethality and availability of fentanyl-laced fake prescription pills. The DEA updated that alert in November 2022 warning that six out of ten fentanyl-laced fake prescription pills contain a potentially lethal dose of fentanyl.

 

 

4/25/23, 9:49 AMDEA Reports Widespread Threat of Fentanyl Mixed with Xylazine | DEA.gov

Page 3 of 3https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine

United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice <https://www.justice.gov/>

<https:/

/www.f

aceboo

k.com/

deahq/

>

<https:/

/www.t

witter.c

om/dea

hq>

<https:/

/www.li

nkedin.

com/co

mpany/

drug-

enforce

ment-

adminis

tration>

<https:/

/www.i

nstagra

m.com/

deahq>

DEA Contact Center

(202) 307-1000 [email protected] Contact the Webmaster </contact-us>